• CureDuchenne Ventures LLC appointed Lidia Gardner as vice president of clinical and medical affairs on May 20, 2026.
• Gardner most recently served as senior medical director, global medical affairs for neurology and immunology at EMD Serono, where she led global medical strategy for neuroimmunology programs.
• She previously held medical affairs and clinical development roles at Novartis, overseeing spinal muscular atrophy and other clinical trials.
• Earlier, she was an associate professor of neurology at the University of Tennessee Health Science Center, where she built and led a translational research program in neuroinflammatory and neuromuscular diseases.
• The role is set to steer medical strategy across CureDuchenne’s research, education, and patient care initiatives, working alongside chief medical advisor Brenda Wong.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CureDuchenne Ventures LLC published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.